| Human |
hsa_circ_CYP24A1 |
hsa_circ_0060927 |
- |
uterine corpus leiomyoma |
CYP24A1 |
miR‐29b‐1‐5p, miR‐224‐3p, miR‐522‐3p, miR‐661, miR‐1264 |
Q
| UP |
More |
| Human |
hsa_circ_CYP24A1 |
hsa_circ_0060937 |
- |
non-small cell lung carcinoma |
CYP24A1 |
- |
Q
M
| UP |
More |
| Human |
hsa_circ_CYP24A1 |
- |
circ-CYP24A1 |
skin squamous cell carcinoma |
CYP24A1 |
- |
Q
S
| UP |
More |
| Human |
hsa_circ_CYP24A1 |
hsa_circ_0060937 |
circ_0060937 |
non-small cell lung carcinoma |
CYP24A1 |
miR-195-5p |
Q
S
| UP |
More |
| Human |
hsa_circ_CYP24A1 |
hsa_circ_0060927 |
circ_0060927 |
colorectal cancer |
CYP24A1 |
miR-331-3p |
Q
| UP |
More |
| Human |
hsa_circ_CYP24A1 |
hsa_circ_0060927 |
circ_0060927 |
oral mucosa leukoplakia |
CYP24A1 |
miR-195-5p |
Q
H
S
| UP |
More |
| Human |
hsa_circ_CYP24A1 |
hsa_circ_0060927 |
- |
renal cell carcinoma |
CYP24A1 |
miR-421 |
Q
H
S
| DN |
More |
| Human |
hsa_circ_CYP24A1 |
hsa_circ_0060927 |
circCYP24A1 |
prostate cancer |
CYP24A1 |
miR-1301-3p |
Q
H
S
| UP |
More |
| Human |
hsa_circ_CYP24A1 |
hsa_circ_0060927 |
circCYP24A1 |
esophageal squamous cell carcinoma |
CYP24A1 |
- |
Q
H
S
| UP |
More |
| Human |
hsa_circ_CYP24A1 |
hsa_circ_0060937 |
- |
lung cancer |
CYP24A1 |
- |
Q
| UP |
More |
| Human |
hsa_circ_CYP24A1 |
- |
circCYP24A1 |
esophageal squamous cell carcinoma |
CYP24A1 |
- |
Q
H
S
| UP |
More |
| Human |
hsa_circ_CYP24A1 |
hsa_circ_0060927 |
circ_0060927 |
non-small cell lung carcinoma |
CYP24A1 |
miR-331-3p |
Q
| UP |
More |
| Human |
hsa_circ_CYP24A1 |
- |
circCYP24A1 |
lung adenocarcinoma |
CYP24A1 |
- |
Q
S
| UN |
More |
| Human |
hsa_circ_CYP24A1 |
hsa_circ_0060927 |
- |
cervical cancer |
CYP24A1 |
hsa-miR-4428, hsa-miR-4433a-3p, hsa-miR-4667-5p, hsa-miR-4780, hsa-miR-5006-5p, hsa-miR-5588-5p, hsa-miR-6875-3p, hsa-miR-6891-5p, hsa-miR-885-3p |
S
| UP |
More |
| Human |
hsa_circ_CYP24A1 |
hsa_circ_0060937 |
Circ_0060937 |
lung cancer |
CYP24A1 |
miR-1304-5p |
Q
| UP |
More |